Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
|Articles|January 11, 2022
Daily Medication Pearl: Tralokinumab-ldrm (Adbry)
Author(s)Saro Arakelians, PharmD
Tralokinumab-ldrm is a human immunoglobulin G4 monoclonal antibody indicated for the treatment of moderate-to-severe atopic dermatitis.
Advertisement
Medication Pearl of the Day: Tralokinumab-ldrm (Adbry)
Indication: Tralokinumab-ldrm (Adbry) is an interleukin-13 (IL-13) antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Insight:
- Dosing: The recommended dosage of Adbry is an initial dose of 600 mg (four 150 mg injections), followed by 300 mg (two 150 mg injections) administered every other week.
- Dosage forms: Injection 150 mg/mL solution in a single-dose prefilled syringe with needle guard.
- Adverse events: Most common adverse events (incidence ≥ 1%) are upper respiratory tract infections, conjunctivitis, injection site reactions, and eosinophilia.
- Mechanism of action: Tralokinumab-ldrm is a human immunoglobulin G4 monoclonal antibody that specifically binds to human IL-13 and inhibits its interaction with the IL-13 receptor α1 and α2 subunits.
- Manufacturer: LEO Pharma
Sources:
Advertisement
Related to this article
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
4
Sotatercept in ERS PAH Guidelines: What Pharmacists Should Watch
5